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Abstract 
This study was performed to determine whether increased ganglioside-specific T cell reactivity can be 
detected in the peripheral blood of patients with Guillain–Barré syndrome (GBS) and chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP). T cell responsiveness to the gangliosides 
GM1, GM3, GD1a, GD1b, GD3, GT1b, GQ1b and sulphatide was assessed in peripheral blood 
mononuclear cells from untreated GBS patients (57), CIDP patients (43), patients with other peripheral 
neuropathies (55) and healthy control subjects (74) in a standard 6-day proliferation assay. Increased T 
cell reactivity to GM1 occurred in GBS patients compared to healthy controls and patients with other 
neuropathies. There was increased reactivity to GM3 in GBS patients compared to patients with other 
neuropathies but not compared to healthy controls. The frequencies of increased T cell reactivity to 
GM1 and GM3 in CIDP patients were intermediate between those of GBS patients and controls. We 
suggest that T cell reactivity to gangliosides might play a contributory role in the pathogenesis of GBS 
and perhaps CIDP.  
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Introduction 
Guillain–Barré syndrome (GBS) is an inflammatory disorder of the peripheral nervous 
system, characterised by the rapid onset of weakness, with disease severity ranging from mild 
symptoms to paralysis. Although most people recover, the duration of the illness may be 
prolonged.1 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is closely 
related to GBS, but is a chronic condition and is distinguished from GBS by its temporal 
pattern, and potential for clinical relapse.2 Recent neurophysiological and pathological 
evidence suggests that GBS comprises a spectrum of diseases that could potentially have 
different pathological mechanisms and targets of immunological attack.3 GBS can be 
subdivided into acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute 
motor and sensory axonal neuropathy (AMSAN) and acute motor axonal neuropathy 
(AMAN).3 Miller Fisher syndrome is a related condition commonly thought to be a variant 
form of GBS. In Western countries, AIDP is the major form of GBS, accounting for 80–90% 
of cases, and involves early lymphocytic infiltration of spinal roots and peripheral nerves and 
macrophage-mediated segmental stripping of myelin.[3] [4] Variability also exists in the clinical 
features of CIDP.5 
Autoimmune responses against peripheral nervous system antigens are believed to be 
important in the pathogenesis of GBS and CIDP.[3] [6] Gangliosides and other glycolipids have 
been increasingly studied as targets of autoimmunity in the nervous system.[7] [8] Gangliosides, 
which are glycolipids containing one or more sialic acid residues in their oligosaccharide 
chains,9 are enriched in the plasma membranes of axons and neuronal cell bodies, and are also 
minor constituents of myelin.10 Ganglioside composition varies in different parts of the 
nervous system.[11] [12] [13]Antibodies specific for more than 20 different glycolipids have now 
been associated with a wide range of acute and chronic neuropathy syndromes, and the 
specificity of these shows some correlation with the clinical pattern of neuropathy.8 
Recent studies have demonstrated that oligoclonal expansion of T cells bearing 
particular T cell receptor Vβ and Vδ genes frequently occurs in GBS patients, suggesting that 
T cells play a role in disease development.14 Because the IgG1 and IgG3 isotypes of anti-
ganglioside antibodies are frequently found in GBS,[8] [15] it is likely that T cell help is 
required for B cell maturation and antibody class switching. Considering the prevalence of 
anti-ganglioside antibodies in neuropathy and the potential role for T cell involvement in 
antibody production, we investigated whether ganglioside-specific T cell reactivity is 
increased in patients with GBS and CIDP. 
 
Materials and methods 
 
Patients 
The numbers, sex, and age statistics of the patient groups used in this study are shown in 
Table 1. Patients with GBS, CIDP and other neuropathies were recruited from hospitals in 
South-East Queensland, Australia. GBS and CIDP patients fulfilled standard diagnostic 
criteria.[16] [17] GBS patients had predominantly demyelinating neuropathy and generally made 
a prompt recovery. Patients with Miller Fisher syndrome were not used in the study. Samples 
were collected from GBS patients within 10 days of the onset of neurological symptoms, 
either before or at the peak of disease, and before administration of any treatment. Follow-up 
blood samples were collected from some patients 3 months after recovery from GBS. GBS 
patient clinical disability was graded on the Hughes Functional Grading Scale (0 = healthy, 
1 = minor symptoms or signs, 2 = independent ambulation, 3 = able to walk 5m with 
assistance, 4 = chair or bed bound, 5 = assisted ventilation for part of the day required, 
6 = death).18  
Table 1. Sample sizes and age data of GBS, CIDP, ON patients and healthy control subjects  
Patient 
group Patient number and age 
 Number (male:female) 
Mean age 
(years) 
Age 
range 
Median 
age 
Mean proliferation assay 
background counts 
(cpm) ± SE 
GBS 57 (38:19) 52 18–82 54 675 ± 97 
CIDP 43 (25:18) 54 18–85 57 759 ± 117 
Healthy 
controls 74 (25:49) 34 21–72 32 745 ± 86 
Other 
neuropathy 55 (28:27) 59 32–80 61 716 ± 115 
Also included is the mean proliferation assay background counts per minute (cpm) ± SE for each of the 
test groups. 
Of the GBS patients, 31% had a mild to medium maximum clinical severity grading of 1–3, 
whilst 69% had more severe clinical severity gradings of 4–5 (27% of 51 patients for whom 
follow-up information was available required mechanical ventilation). For GBS patients, 
information regarding potential precipitating factors, including recent infections or 
vaccinations prior to the onset of neurological symptoms, was recorded for 52 of the 57 
patients studied. Of these, 29 patients (56%) had upper respiratory tract infection, 9 (17%) 
gastrointestinal infections, 2 (4%) recent influenza vaccinations, 1 Epstein–Barr virus 
infection, 1 uveitis, and 2 fever of unknown origin. Eight remaining patients (15%) had no 
identifiable precipitating factors. 
CIDP patients had not received any immunosuppressive medications, corticosteroids, 
intravenous immunoglobulin or plasma exchange for at least 2 months prior to blood 
collection. Patients with other neuropathies (ON) included patients with hereditary motor 
sensory neuropathy, toxic neuropathy and diabetic neuropathy. Healthy controls were 
recruited from hospital staff and at the time of blood collection had no symptoms of any 
infectious illnesses. 
All blood samples were collected after written consent was obtained from each 
patient. This study was approved by the Human Research Ethics Committees of the Royal 
Brisbane, Princess Alexandra, Mater, Greenslopes Private, and Logan Hospitals, as well as 
the Medical Research Ethics Committee of The University of Queensland. 
 
Antigens 
Bovine gangliosides GM1, GD1b, GT1b and sulphatide (S) were purchased from Sigma (St. 
Louis, MO, USA), whilst GM3, GD1a, GD3 and GQ1b were purchased from Alexis 
Biochemicals (Switzerland). Structures of gangliosides used in the study are shown in Fig. 1. 
To determine the optimal physiological concentration of gangliosides for use in T cell 
proliferation assays, cells from patients and healthy controls were tested in culture against a 
variety of concentrations ranging from 10 µg/ml to 0.005 ng/ml. Tetanus toxoid was obtained 
as a gift from the Commonwealth Serum Laboratories (CSL; Melbourne, Australia). 
Phytohaemagglutinin (PHA) was obtained from Sigma (St. Louis, MO, USA).  
 
Fig. 1. Structures of gangliosides and sulphatide used in this study. Glc = glucose; Gal = galactose; 
GalNAc = N-acetylgalactosamine; NeuAc = N-acetylneuraminic acid; cer = ceramide. 
 
Tissue typing 
Genomic DNA was prepared from heparinised whole blood either by using Nucleospin Blood 
XL DNA extraction kits (Macherey-Nagel, Düren, Germany) or overnight digestion with 
sodium dodecyl sulphate/proteinase K, followed by salting out of high molecular weight 
DNA. HLA DRB1, DQA1 and DQB tissue typing was performed using SSP HLA typing kits 
(Dynal Biotech, Oslo, Norway). 
 
Anti-GM1 enzyme linked immunosorbent assay 
Details of enzyme linked immunosorbent assay (ELISA)-based methods for detection of anti-
GM1 IgG and IgM antibodies in GBS patient sera have been presented previously.19 
 
Proliferation assays 
Peripheral blood ( 60 ml) was collected by venepuncture from each subject after informed 
written consent had been obtained. Peripheral blood mononuclear cells (PBMC) were 
separated from heparinised blood by centrifugation through Histopaque (Sigma, St Louis, 
MO, USA) and washed twice. One hundred thousand PBMC were cultured in 200 µl/well in 
quadruplicate cultures with and without test antigens in 96-well round-bottomed microtitre 
plates (Nunc, Denmark) in RPMI-1640 media supplemented with 10% heat-inactivated 
pooled human serum, 2 mM l-glutamine and 10 mM Hepes buffer. Cultures were incubated 
for 6 days, with 0.5 µCi [3H]thymidine being added during the last 18 h of culture. Cultures 
were harvested and thymidine uptake was measured in counts per minute in a β-plate counter 
(LKB-Wallace, Turtu, Finland). Each ganglioside was tested at a range of five concentrations 
(1, 0.1, 0.05, 0.01 and 0.005 ng/ml). The stimulation index (SI) was determined by the 
formula: SI = (mean cpm of quadruplicate, ganglioside-containing wells)/(mean cpm of 24 
control wells, without antigen). A positive proliferative response for each test subject’s cells 
was scored if the patient’s cells responded to the ganglioside tested at any one of the five 
concentrations with an SI  2.0. Individual assays with control background counts of less 
than 150 cpm, or greater than 5000 cpm were considered outside the normal range and 
rejected from the data set. Mean and standard error values for background counts for each 
patient group can be found in Table 1. Tetanus toxoid and the mitogen PHA were used to 
assess the viability and strength of cellular reactivity in each subject’s cells. 
 
Statistical analysis 
In the different patient groups, the percentages of individuals making a positive proliferative 
response to gangliosides were compared using the χ2 test with Yates’ correction applied as 
required. Odds ratios (OR) with upper and lower 95% confidence intervals were also 
calculated for selected comparisons. Mean SI values were compared using analysis of 
variance (ANOVA) to compare all the test groups simultaneously. F-tests were used to 
determine whether the variances between test group stimulation indices were significantly 
different, followed by the appropriate Student’s t test to compare pairs of groups. A 
comparison was deemed to show statistical significance if p  0.05. 
T cell reactivity to different antigens in the patient groups (GBS or CIDP) was 
deemed to be of significance only if both the comparison of the percentages of patients 
showing increased T cell reactivity, and the comparison of the T cell reactivity mean SI 
values were significantly increased when compared to both healthy controls and ON patients. 
 
Results 
 
T cell reactivity to gangliosides: frequencies of responses with an SI  2.0 
The percentages of individuals in each subject group with a T cell reactivity SI  2.0 were 
determined for each ganglioside and compared by χ2 analysis (Fig. 2). The percentage of GBS 
patients reacting with an SI  2.0 to GM1 was 35%, which was significantly higher than the 
percentage of healthy subjects (12%) and of ON patients (9%). Although the percentage of 
CIDP patients with an SI  2.0 for GM1 reactivity (23%) was higher than that of healthy 
controls and ON patients, this increase was not statistically significant.  
 Fig. 2. Percentages of patients with GBS, CIDP, healthy control subjects (HC) and other neuropathy 
patients (ON) responding with an SI  2.0 to specific gangliosides. The p values for the comparisons 
of the responses of the four groups together (4 × 2) and the p values for the comparisons of the pairs of 
groups (χ2 analysis) are shown directly below the ganglioside to which they refer. S = sulphatide. 
The proportions of patients showing an SI  2.0 for GM3 T cell reactivity in GBS patients 
(22%) were significantly higher than those obtained for both healthy controls (9%) and ON 
patients (0%). CIDP patient anti-GM3 reactivity (18%) was significantly greater than that of 
ON patients (0%), but not significantly greater than healthy controls (9%). The percentage of 
CIDP patients with increased T cell reactivity to GD3 (18%) was significantly higher than 
that of ON patients (2%), but not that of healthy controls (8%). Seven of the 20 GBS patients 
(35%) with increased T cell reactivity to GM1 also had increased reactivity to GM3, and of 
the 11 GBS patients with increased reactivity to GM3, 7 (63%) displayed increased anti-GM1 
reactivity. Table 2 shows the detailed statistical comparison of reactivity to GM1 and GM3 
between pairs of test groups. Ten GBS patients who initially responded to GM1 were re-
tested for reactivity 3 months after disease recovery. Only one of these patients retained 
increased T cell reactivity to GM1. 
Table 2. χ2 p values, odds ratios and upper and lower 95% odds ratio confidence intervals for 
multiple two-way comparisons for increased T cell reactivity to GM1 and GM3  
Comparison GM1 GM3 
 p value 
Odds 
ratio 
Upper and lower 
95% CI 
p 
value 
Odds 
ratio 
Upper and lower 
95% CI 
GBS vs. HC 0.002 3.90 1.61–9.45 0.035 3.00 1.03–8.78 
GBS vs. ON 0.002 5.40 1.85–15.73 0.002 13.25 1.60–107.2 
CIDP vs. HC 0.117 2.00 0.74–5.39 0.090 2.37 0.70–8.01 
CIDP vs. 
ON 0.099 2.77 0.87–8.82 0.009 10.44 1.19–91.4 
The percentages of GBS and CIDP patients with increased T cell reactivity to the 
gangliosides GD1a, GD1b, GT1b, GQ1b and sulphatide were not significantly greater than 
those of healthy controls or ON patients. There were no significant differences in anti-
ganglioside reactivity between GBS patients and CIDP patients. 
T cell reactivity to gangliosides: mean stimulation indices 
Fig. 3 shows a scatter plot of individual patients’ proliferative responses to GM1 and GM3. 
For GM1, the mean maximum SI for GBS patients (2.43 ± 0.53) was significantly higher than 
for healthy controls (1.43 ± 0.07; p = 0.036) and ON patients (1.28 ± 0.09; p = 0.037). For 
GM3 reactivity, the mean maximum SI for GBS patients (1.52 ± 0.13) was significantly 
greater than that of ON patients (1.20 ± 0.04; p = 0.038), but not than that of healthy controls 
(1.37 ± 0.07). Of the GBS patients reacting to GM1 with an SI  2.0, the mean SI was 
4.69 ± 1.42 (range 2.06–28.67). Of the positive GBS responders to GM3, the mean SI was 
2.93 ± 0.92 (range 2.02–5.17). For the gangliosides GD1a, GD1b, GD3, GT1b, GQ1b and 
sulphatide, there were no significant differences in means of stimulation indices between GBS 
or CIDP and healthy controls and ON patients.  
 Fig. 3. Scatter plot of T cell reactivity to GM1 and GM3 expressed as stimulation indices for each 
patient in each of the test groups. Filled black circles indicate the mean stimulation index for each 
group, whilst error bars indicate standard error. 
T cell reactivity to tetanus toxoid 
For all assays, tetanus toxoid was included as a known, strong inducer of recall T cell 
reactivity, and serves as a useful indicator for comparison with anti-ganglioside specific 
responses. Table 3 shows the percentages of positive T cell reactivity as well as the 
means ± SE of tetanus toxoid-specific responses in each of the test groups. The p values for 
comparison of frequencies of increased reactivity and for comparison of means between pairs 
of test groups are also shown. No significant differences in proportions of tetanus toxoid-
specific T cell reactivity were seen in GBS patients when compared to healthy controls or ON 
patients. CIDP patients had significantly lower reactivity than healthy controls, but not 
compared with ON patients.  
Table 3. Frequencies (%) and mean maximum stimulation indices (SI ± SE) of T cell reactivity to 
tetanus toxoid for GBS, CIDP, ON patients and healthy controls  
Patient group Frequency SI  2 tetanus toxoid Mean SI ± SE tetanus toxoid 
GBS 73.8% 27.9 ± 5.4 
CIDP 66.7% 20.5 ± 4.1 
Healthy controls 83.5% 35.3 ± 4.9 
Other neuropathy 72.1% 34.5 ± 6.2 
   
Groups compared χ2 p values Student’s t test p values 
GBS vs. HC 0.150 0.317 
GBS vs. ON 0.838 0.426 
CIDP vs. HC 0.021 0.034 
CIDP vs. ON 0.525 0.069 
Student’s t test was used to compare the means of pairs of test groups, whilst the χ2 test was used to 
compare frequencies of reactivity between test groups. 
Correlation of T cell reactivity with clinical features and HLA typing 
Table 4 compares GBS patient anti-GM1 T cell reactivity with positive anti-GM1 antibody 
titre, disease severity as denoted by requirement for patient ventilation, and antecedent illness. 
The proportion of patients with increased IgG or IgM anti-GM1 antibody levels was higher in 
patients with increased GM1-specific T cell reactivity (67%) than in patients without elevated 
T cell reactivity to GM1 (41%), although this was not significant.  
Table 4. Comparison of GBS patient T cell reactivity to GM1 ganglioside with positive anti-GM1 
antibody titre, disease severity and antecedent illness  
Total GBS 
patients 
GM1 T cell 
reactivity 
IgG or IgM GM1 
antibody 
Disease severity 
(ventilation required) 
Antecedent 
illness 
  8 +ve (67%) 1 ventilated (6%) 8 URTI (42%) 
n = 57 20 +ve (35%) 4 −ve (33%) 17 not ventilated (94%) 5 gastro (26%) 
  8 not tested 2 not known 2 other (11%) 
    4 none (21%) 
    1 not known 
     
  9 +ve (41%) 13 ventilated (39%) 21 URTI (64%) 
 37 −ve (64.9%) 13 −ve (59%) 20 not ventilated (61%) 4 gastro (12%) 
  15 not tested 4 not known 4 other (12%) 
    4 none (12%) 
    4 not known 
 
Interestingly, only one (6%) of 18 GBS patients who had increased T cell reactivity to GM1 
required ventilation (disease severity score of 5), whereas ventilation was required in 13 
(39%) of 33 patients who did not have increased T cell reactivity. This negative association 
between disease severity and anti-GM1 T cell reactivity was statistically significant 
(p = 0.023, OR = 0.09, 95% CI of OR = 0.011–0.76). 
When GBS patients were divided into two groups based on the type of preceding 
infection prior to onset of neurological symptoms, 56% (5 of 9 patients) with gastrointestinal 
infections as a preceding illness had increased T cell reactivity to GM1, whereas only 26% (8 
of 29 patients) with non-specific upper respiratory tract infections as a preceding illness 
displayed increased reactivity to GM1, although this was not statistically significant. 
HLA-DR and HLA-DQ typing of GBS patients revealed no associations between T 
cell reactivity to GM1 or any of the other gangliosides tested and HLA-DR or HLA-DQ type 
(either at the molecular level, or when results were grouped into conventional serological 
typing groups). 
 
Discussion 
The present study has shown that patients with GBS have increased circulating T cell 
reactivity to GM1 compared to healthy controls and ON patients. The finding of elevated 
reactivity in GBS patients, but not in patients with other peripheral neuropathies, shows that 
the immunoreactivity is not a consequence of peripheral nerve damage. Indeed, the T cell 
reactivity against GM1 tended to be lower in patients with other neuropathies than in healthy 
controls, as we have previously reported for T cell reactivity to gangliosides in patients with 
central nervous system diseases other than multiple sclerosis.20 Elevated T cell reactivity to 
GM1 in GBS patients is congruent with previous reports of elevated anti-GM1 antibodies in 
patients with either demyelinating or axonal forms of GBS.[21] [22] [23] [24] [25] [26] [27] In the 
present study, there was an increased frequency of elevated anti-GM1 antibody levels in those 
GBS patients demonstrating increased T cell reactivity to GM1, although this failed to reach 
statistical significance. GM1 is relatively enriched in human ventral roots compared with 
dorsal roots,28 and antibodies specific to GM1 are commonly associated with motor 
neuropathy, especially axonal forms of GBS,27 CIDP and multifocal motor neuropathy. As the 
majority of our patients had demyelinating forms of GBS, we were unable to examine the 
frequency of GM1 reactive T cells in axonal forms of GBS. 
Recently, the role of the MHC-like CD1 family of molecules in presentation of lipid 
and glycolipid antigens to T cells and natural killer T (NKT) cells has been elucidated. T cells 
and NKT cells of both pro-inflammatory and immunoregulatory phenotypes can be stimulated 
by presentation of lipid and glycolipid antigens through CD1, suggesting that CD1-restricted 
T cells and NKT cells might play a role in determining the balance between tolerance and 
autoimmunity to these antigens.29 GM1-specific T cell clones have been produced from the 
peripheral blood of MS patients and shown to be restricted by CD1b,[30] [31] which is expressed 
by dendritic cells, but not by monocytes and macrophages in the blood. 
Generally, the stimulation indices of ganglioside-specific T cell reactivity was of a 
lower level than responses to MHC class II-restricted control antigens like tetanus toxoid. Our 
assay system could have been limited by a lack of cells capable of presenting gangliosides to 
CD1b-restricted ganglioside-specific T cells, and could have under-estimated the level of 
reactive cells as dendritic cell numbers in the blood are generally much lower than the levels 
of monocytes and macrophages. Indeed, as we found no correlation of HLA-DR or HLA-DQ 
typing with anti-GM1 T cell reactivity in our GBS patients, it is possible that these T cells are 
CD1 restricted. Gangliosides are relatively insoluble in aqueous solutions, and this could also 
influence the efficiency of their uptake and presentation by antigen-presenting cells in our 
assay cultures. 
There was no significant difference in reactivity to the positive control antigen 
tetanus toxoid between GBS patients and healthy controls or ON patients. 
Ninety percent of GBS patients showing increased anti-GM1 T cell reactivity did not have 
increased reactivity 3 months after recovery from the disease, perhaps indicating a lack of 
induction of conventional T cell memory mechanisms, or that these cells are deleted from the 
T cell repertoire during recovery from GBS. 
Despite many reports characterising specificity of anti-ganglioside antibodies in 
inflammatory neuropathy, this is the first report of ganglioside-specific T cells in GBS and 
CIDP. Recently, there has been a report that GBS patients might show T cell proliferation in 
response to non-protein antigens of Campylobacter jejuni, which could represent a response 
to gangliosides found in C. jejuni32 Chemical studies of the core oligosaccharide of C. jejuni 
lipo-oligosaccharides have revealed structures that mimic human gangliosides including 
GM1, GD1a, GD2, GD3, and GM2,33 strengthening the view that molecular mimicry between 
pathogen glycolipids and self-gangliosides, particularly GM1, could be an important factor in 
the pathogenesis of GBS.34 It has been generally found that GBS follows gastrointestinal or 
respiratory infections in two-thirds of cases.4 Seventy-three percent of the GBS patients in this 
study had preceding non-specific upper respiratory tract or gastrointestinal infections prior to 
the onset of neurological symptoms. Although not statistically significant, we found that a 
greater proportion of patients with preceding gastrointestinal infections had increased anti-
GM1 T cell reactivity than did those patients with preceding non-specific upper respiratory 
tract infections. In GBS, anti-GM1 antibodies have been found to be associated with severe 
cases and a poor prognosis, and also with GBS following infection with C. jejuni[23] [24] [35] In 
contrast to the finding that anti-GM1 antibodies are associated with more severe forms of 
GBS, we found that patients with increased anti-GM1 T cell reactivity were significantly less 
likely to need mechanical ventilation than those without such reactivity. This raises the 
possibility that increased GM1-specific T cell reactivity might have an immunoregulatory or 
neuroprotective role. 
Antibody reactivity to GD1a has been found in patients with acute motor axonal 
neuropathy and predominantly motor forms of GBS,[36] [37] and antibodies to GD1a 
preferentially label motor fibres whereas antibodies to GD1b preferentially label large dorsal 
root ganglion neurons.13 We did not find significantly increased T cell reactivity to GD1a in 
our patients with GBS or CIDP, possibly because the majority of our GBS patients had 
predominantly demyelinating, rather than axonal forms of disease. Antibody to GD1b and 
GT1b has been found in patients with predominantly sensory neuropathy,[38][39][40] but we did 
not find increased T cell reactivity to these antigens in the present study, possibly because our 
patients had predominantly motor neuropathies. Similarly, we found no elevated reactivity to 
sulphatide, although this has also been a target of antibody in neuropathy.41 
CIDP patients had increased T cell reactivity to the gangliosides GM1, GM3, GD3 and 
possibly GQ1b more frequently than healthy controls and ON patients but the differences 
were not statistically significant. The proportions of CIDP patients with increased T cell 
reactivity to gangliosides may be an underestimate, as it is possible that the level of this 
reactivity may fluctuate with the disease course of CIDP, as we have demonstrated for T cell 
reactivity to myelin antigens in multiple sclerosis.42 Although CIDP patients had not received 
any immunomodulatory therapy for at least 2 months prior to blood collection, previous 
treatments in some patients might have reduced the levels of ganglioside-specific T cells. 
Gangliosides could still represent targets of autoimmune T cell attack in CIDP. Studies of 
nerve biopsies from CIDP patients have revealed evidence of NKT and T cells of a γδ TCR 
phenotype, consistent with a possible role for cellular immune responses against non-protein 
antigens.[43] [44] 
The present study does not directly determine whether these ganglioside-specific T 
cells contribute to the pathogenesis of inflammatory neuropathy. Previous experimental 
evidence in animal models indicates that autoreactivity to gangliosides can cause 
neuropathy,[45] [46] [47] and a positive association between injection of patients with bovine 
gangliosides and increased incidence of GBS provides further evidence.[8] [48] One possible 
role for ganglioside-reactive T cells might be to facilitate production of antibody that may 
itself have a role in pathogenesis. Indeed, it has been shown that the B cells producing GM1 
antibody in GBS and multifocal motor neuropathy are T cell dependent,49 whilst T cells of the 
γδ type have been found in the blood of patients with GBS and were thought to provide help 
for glycolipid antibody production.50 Ganglioside-reactive T cells may also have a more direct 
role in pathogenesis. In GBS and CIDP, there is infiltration of the nerves with T cells and 
macrophages.[3] and [6] In experimental allergic neuritis, an animal model of GBS, both NK 
cells and γδ T cells have been found in the nerves, where they could play a direct role in 
pathogenesis,51 or in providing B cell help.52 In GBS, γδ T cells have been cultured from 
nerve biopsies, where they have been thought to have a role in responding to non-protein 
antigens,[44] [53] and oligoclonal expansion of T cells bearing particular T cell receptor Vβ and 
Vδ genes frequently occurs in GBS, suggesting that T cells play a role in disease 
development.14 
In GBS, ganglioside-specific T cells could cause damage to nerves through a number 
of mechanisms including direct axonal or Schwann cell cytotoxicity, or by secretion of 
proinflammatory cytokines to induce damage directly or act to recruit and activate 
macrophages. Early infiltration of nerves with activated, pro-inflammatory T cells could help 
to open the blood–nerve barrier to pathogenic antibody.54 Alternatively, specific sub-
populations of ganglioside-specific T cells could act by the secretion of downregulatory 
cytokines to terminate the acute inflammatory process. 
In summary, we report the finding of increased T cell reactivity to GM1 in GBS 
patients, and suggest that further studies are required to characterise these cells 
phenotypically, to determine whether they contribute to the pathogenesis of disease, or serve 
to act in an immunoregulatory or neuroprotective capacity.  
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